Microenvironment and Immunology

Effects of Notch Signaling on Regulation of Myeloid Cell Differentiation in Cancer

Pingyan Cheng¹, Vinit Kumar², Hao Liu¹, Je-In Youn², Mayer Fishman¹, Simon Sherman³, and Dmitry Gabrilovich¹,²

Abstract

Functionally altered myeloid cells play an important role in immune suppression in cancer, in angiogenesis, and in tumor cells' invasion and metastases. Here, we report that inhibition of Notch signaling in hematopoietic progenitor cells (HPC), myeloid-derived suppressor cells (MDSC), and dendritic cells is directly involved in abnormal myeloid cell differentiation in cancer. Inhibition of Notch signaling was caused by the disruption of the interaction between Notch receptor and transcriptional repressor CSL, which is normally required for efficient transcription of target genes. This disruption was the result of serine phosphorylation of Notch. We demonstrated that increased activity of casein kinase 2 (CK2) observed in HPC and in MDSC could be responsible for the phosphorylation of Notch and downregulation of Notch signaling. Inhibition of CK2 by siRNA or by pharmacological inhibitor restored Notch signaling in myeloid cells and substantially improved their differentiation, both in vitro and in vivo. This study demonstrates a novel mechanism regulation of Notch signaling in cancer. This may suggest a new perspective for pharmacological regulation of differentiation of myeloid cells in cancer. Cancer Res; 74(1): 141–52. ©2013 AACR.

Introduction

There is now ample evidence supporting the critical role of myeloid cells in tumor progression. The major changes that are observed in the myeloid compartment include accumulation of myeloid-derived suppressor cells (MDSC), defects in differentiation of dendritic cells, and accumulation and polarization of tumor-associated macrophages (1). Although some specific proteins factors such as STAT3, CEBP/β, PIR-B, NF-κB, and COX (2–12) were implicated in abnormal myeloid cell differentiation, this process remains unclear, which limits therapeutic targeting of myeloid cells.

Myeloid cell development in bone marrow is regulated by complex network of cytokines and by the direct physical interaction between hematopoietic progenitor/stem cells (HPC) and stromal cells (reviewed in ref. 13). Signaling through the Notch family of transcriptional regulators plays a major role in the direct interaction between HPC and stroma. Each member of Notch family is a large, single heterodimeric receptor composed of noncovalently associated extracellular (ECN), transmembrane (TMN), and intracellular (ICN) sub-units. The ICN region contains an RBPjκ association module (RAM) domain that binds the transcriptional repressor CSL (CBF-1, RBP-J), a series of cdc10/ankyrin repeats (ANK domain) that are involved in protein–protein interactions with CSL/CBF-1 and other polypeptides, and a C-terminal PEST sequence responsible for the degradation of the ICN signal. At present, 2 major Notch ligand families, Delta (Dll, Dll1-4) and Jagged (Jag, Jag1-4), have been described. Binding of the ECN domain of Notch by a Notch ligand results in the cleavage of ICN and its translocation to the nucleus where, together with number of recruited coactivators, it interacts with CSL. The binding of ICN with CSL displaces corepressor complexes, thereby activating transcription from promoters with CSL binding elements. In mammals, targets of ICN/CSL signals include genes of the Hairy/Enhancer of Split (HES) family, HRT/HERP genes, cyclin D1, p21, NF-κB, and many others (14–17).

Available data provide a consensus view on the critically important role of Notch signaling in myeloid cell differentiation. However, the exact nature of Notch effects remains controversial. Some existing data demonstrated the critical role of Notch in maintenance of progenitor cells and blockade of terminal differentiation of myeloid cells, whereas the other data showed requirements of Notch signaling for differentiation of mature myeloid cells (reviewed in ref. 18). It seems that the impact of Notch signaling depends on the stage of myeloid cell differentiation when Notch activation is triggered, the presence of specific cytokines, and on whether activation of Notch signaling was triggered by soluble or immobilized ligands. A number of studies have demonstrated that Notch signaling is important for dendritic cell differentiation (19–26). Notch signaling was shown to be also important for macrophage...
localization and for interactions of endothelial cells during sprouting angiogenesis (27). Notch was also implicated in accumulation of immature myeloid cells (IMC) that can be defined as Gr-1\(^+\)CD11b\(^+\), in mice. With overexpression of ADAM10, which is involved in the cleavage of ICN, systemic expansion of Gr-1\(^+\) CD11b\(^+\) was observed (28).

In this study, we investigated possible changes in Notch signaling in myeloid cells in cancer and the consequences of those changes for differentiation of myeloid cells. We present evidence indicating that downregulation of Notch signaling plays a major role in abnormal myeloid cell differentiation in cancer. Furthermore, this inhibition could be caused by the disruption of physical interaction between Notch and CSL and implicated upregulation of casein kinase 2 (CK2) activity in that disruption.

Materials and Methods

Mice and tumor models

Six- to eight-week-old female BALB/c, C57BL/6, and CD45.1\(^+\) mice were purchased from the National Cancer Institute. All animal experiments were approved by the University of South Florida Institutional Animal Care and Use Committee. EL4 lymphoma, CT26 colon carcinoma, and MethA sarcoma were established by subcutaneous injection of 5 \(\times\) 10\(^5\) cells into C57BL/6 (EL-4) or BALB/c (CT26, MethA) mice. In most experiments, cells were analyzed 3 weeks after tumor injection when tumor reached 1.2 cm in diameter.

Human subjects and isolation of cells

Six patients with renal cell carcinoma were enrolled to the study after signing informed consent form approved by the University of South Florida Internal Review Board. Samples of peripheral blood from 5 healthy volunteers were obtained from blood bank. Mononuclear cells were isolated using a Ficoll gradient density centrifugation. Monocytes (healthy donors) and MDSC (cancer patients) were collected from mononuclear fraction and CD14\(^+\) CD11b\(^+\)CD15\(^+\) and CD14\(^+\) CD11b\(^-\)CD15\(^-\) cells were sorted by FACSaria cell sorter (BD Biosciences). PMNs were collected after centrifugation on 63 of 72% Percoll gradient above 72% Percoll layer and CD14\(^-\) CD11b\(^+\)CD15\(^-\) cells were sorted. The list of reagents is provided in supplementary data.

Isolation of mouse cells

Bone marrow cells were enriched for HPCs by depletion of lineage-specific cells with lineage depletion kit (Miltenyi Biotec). Isolation of the populations of myeloid cells was performed using biotinylated CD11c, Gr-1, or PE-conjugated c-Kit antibodies followed by MiniMACS microbeads (Miltenyi Biotec). The purity of the cells was consistently more than 92% in all samples. In some experiments, Gr-1\(^+\)CD11b\(^+\) cells were sorted using FACSaria cell sorter (BD Biosciences).

CK2\(\alpha\) and Notch 1 constructs and transfection

CK2\(\alpha\) plasmid pZW6 was obtained from Addgene. pcDNA3.1-ICN1-Myc plasmid was kindly provided by Dr. B. Osborne, University of Massachusetts, Amherst, MA. Preparation of retroviruses expressing CK2, ICN1-Myc, and mutant constructs is described in supplementary data. All retroviruses were generated by cotransfection of the constructs with pCL-Eco into the packaging cell line 293T using Geneporter-2 (Genlantis). The retroviral supernatants were harvested 48-hour posttransfection and used for infection of cells for 4 hours at 32°C in the presence of 4 \(\mu\)g/mL Polybrene (Sigma). After that time, viral supernatants were removed and complete culture medium supplemented with GM-CSF was added. Cells were cultured for 20 hours at 37°C, and then infection was repeated.

Cell cultures on Notch ligands and differentiation of dendritic cell

Fibroblast cell line expressing Jag1 was described previously (29). HPCs were cultured on the monolayer of irradiated (25 Gy) fibroblasts in the presence of 20 ng/mL GM-CSF, CD45\(^+\) hematopoietic cells were isolated using microbeads and MiniMACS columns with more than 93% purity. Culture of HPC on Dll1 immobilization on plastic was performed as described previously (29). Dendritic cells were generated from enriched bone marrow HPCs for 7 days with 20 ng/mL GM-CSF and tumor-conditioned media (TCM; 30%, v/v). For dendritic cell activation, LPS 1 \(\mu\)g/mL was added 24 hours before cell analysis. For human cell cultures, CD34\(^+\) cells were cultured in medium supplemented with 20 ng/mL of GM-CSF and 20 ng/mL of IL-4. TCM from human breast carcinoma MCF7 and small lung cancer 81M1 cell lines were added at 30% (v/v).

Dendritic cell differentiation in vivo

Bone marrow cells obtained from naïve C57BL/6 mice (CD45.2) were depleted from lineage-positive cells using lineage cell depletion kit (Miltenyi Biotec) followed by sorting of lineage negative and c-kit positive cells using a FACSaria. Lin\(^-\)c-Kit\(^+\) progenitor cells were cultured in myeloid long-term culture medium for primitive mouse hematopoietic cells, supplemented with 20 ng/mL of SCF, FLT3L, IL-6, and IL-11 as previously described (30). On days 1 and 2, cells were infected with retroviruses expressing ICN1-GFP. On day 4, 10\(^5\) cells were injected intravenously into lethally irradiated (9.5 Gy) naïve or EL4 tumor-bearing (TB) CD45.1 congenic mice with 0.5 \(\times\) 10\(^6\) host whole bone marrow cells. Analysis was performed on day 12 after the cell transfer with CD45.2 and GFP double positive cell used for the analysis.

Allogeneic mixed leukocyte reaction

Splenocytes from naïve or TB Balb/c mice were irradiated at 20 Gy and mixed in triplicates with 2 \(\times\) 10\(^5\) T cells from naïve C57BL/6 mice at different ratios. [\(\mathrm{HT}\)]-thymidine (1 \(\mu\)Ci) was added 18 hours before cell harvesting. Radioactivity was counted on a liquid scintillation counter (Packard Instrument).

TBCA treatment in vivo and in vitro

CT26 TB mice were treated with tetramethylsuccinamic acid [(E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid, TBCA; 1.7 mg in 200 \(\mu\)L dimethyl sulfoxide (DMSO)/water (1:4), i.p. daily for 6 days] or vehicle alone. Next day after the last treatment, mice were sacrificed and analyzed. For in vitro treatment, HPCs from naïve bone marrow were cultured in the presence TCM. TBCA (0.6–2.5 \(\mu\)mol/L) was added and medium was changed every day.
Western blot assay, immunoprecipitation, and electrophoretic mobility shift assay

Nuclear extracts were prepared and Western blotting was performed as described previously (29). Immunoprecipitation was carried out using 800 μg to 1.2 mg of whole cell lysates. Electrophoretic mobility shift assay (EMSA) was performed as previously described (31) and details are provided in supplementary data.

siRNA transfection

The cells were mixed with 100 nmol/L Silencer Select Pre-Designed siRNA (Csnk2a1) specific to sequences encoding CK2α exon 8, and another siRNA for exon 9 for confirmation and scrambled siRNA (Invitrogen) for control. The transfection was carried out using an Amaxa Nucleofactor Kit (Lonza). After 24 to 48 hours, the cells were collected and Hes 1 expression was analyzed by quantitative real-time PCR.

Real-time quantitative PCR

PCR was performed with TaqMan Universal PCR Master Mix (Applied Biosystems), and target gene assay mix containing sequence-specific primers for hes1, hes5, notch 1, notch 2, and 6-carboxyfluorescein (6-FAM) dye-labeled TaqMan minor groove binder (MGB) probe (Applied Biosystems). Amplification was performed with 185 endogenous control assay mix was used for controls. Data quantitation was performed using the relative standard curve method or ΔCT. Expression levels of the genes were normalized by 18S rRNA.

Luciferase reporter assay

For the analysis of CSL luciferase activity, we used Notch reporter retroviral construct containing CSL responsive element (31). Activity was measured 18 hours after infection in duplicates on a Lumat LB 9501 luminometer (Berthold) and normalized to protein concentration.

CK2 activity

CK2 activity of whole cell lysates was measured using Millipore Assay Kit after precipitation of 750 μg of protein with CK2αt antibody.

Statistical analysis

Statistical analysis was performed using a 2-tailed Student t test and GraphPad Prism 5 software (GraphPad Software Inc.), with significance determined at P < 0.05.

Results

Downregulation of Notch signaling in HPC and myeloid cells in tumor-bearing hosts

Impairment of differentiation of myeloid cells from HPC in the presence of TCM manifests in decreased proportion of CD11c+MHC class II+ dendritic cells and accumulation of Gr-1+CD11b+ MDSC (Fig. S1A). In TB mice, the proportion of CD11c+MHC class II+ dendritic cells in spleens was substantially reduced, whereas the proportion of Gr-1+CD11b+ MDSC was dramatically increased (Supplementary Fig. S1B).

To evaluate the role of Notch signaling in myeloid cell differentiation in cancer, we studied 3 populations of cells, which represent sequential stages of myeloid cell differentiation: (1) bone marrow CD34+ HPC; (2) spleen Gr-1+CD11b+ cells, which in naïve mice represent mixed population of precursors of myeloid cells, IMC; and in TB mice are characterized as MDSC (32); and (3) spleen CD11c+ MHC class II+ dendritic cells.

Expression of Notch target genes hes1 and hes5 was dramatically reduced in all 3 populations of cells isolated from TB mice as compared with the cells from naïve mice (Fig. 1A and B). In recent years, 2 subsets of MDSC were identified (1): CD11b+Ly6C+Ly6G− monocytic MDSC (M-MDSC) representing ~10% of all MDSC and CD11b+Ly6C−Ly6G+ polymorphonuclear MDSC (PMN-MDSC) representing ~90% of these cells (Supplementary Fig. S1C). We compared the expression of Notch target genes in these populations sorted from bone marrow of TB mice with monocytes and PMN with the same phenotype sorted from bone marrow of control mice. PMN-MDSC but not M-MDSC had significantly lower expression of hes1 and hes5 than their control counterparts (Fig. 1C).

The activity of Notch signaling was further analyzed by measurement of the binding of transcriptional factor CSL/CBF1 to its DNA consensus sequence using EMSA. The CSL/ CBF1-specific binding in HPCs from TB mice was substantially lower than the binding in HPCs from control mice (Fig. 1D). The CSL/CBF1 DNA binding activity was also evaluated in luciferase reporter assay. Notch activity in HPCs from TB mice was significantly (P < 0.01) lower than in HPCs from naïve mice. This effect was observed also when Notch signaling was activated by culturing HPCs on a monolayer of fibroblasts expressing Jag1 (Fig. 1E). Similar experiments were performed with Gr-1+CD11b+ cells isolated from spleens of TB and naïve mice. MDSC from TB mice had significantly (P < 0.001) lower Notch activity than was observed in the IMC from the control mice (Fig. 1F).

Notch activity (HES1 expression) was evaluated in CD14−CD11b+CD15− granulocytes isolated from peripheral blood of healthy donors and PMN-MDSC with the same phenotype isolated from patients with renal cell carcinoma. Expression of HES1 in the cells from patients with cancer was significantly lower than in those from the healthy donors (Fig. 1G). A similar effect, albeit less pronounced, was observed in testing the population of CD14−CD11b+CD15− monocytes (Fig. 1G). Three-day culture of human CD34+ HPC with TCM from breast carcinoma MCF7 and small cell lung cancer cell line 811M1 caused significant (P < 0.01) decrease in the expression of HES1 (Fig. 1H). These data indicate that Notch activity was strongly decreased in HPC and myeloid cells in TB mice, and in myeloid cells obtained from patients with kidney cancer.

The role of ligands and receptors in causing decreased Notch signaling in HPC and in myeloid cells in cancer

We evaluated the major components of ternary complex responsible for Notch signaling. The amounts of ICN1, ICN2 (2 major Notch receptors in HPC), and CSL in nuclear extracts from bone marrow HPCs were similar in control and TB mice (Fig. 2A). For both control and TB mice, similar levels of expression of notch1 and notch2 mRNA were observed in the bone marrow HPC and spleen-derived dendritic cells.
Expression of *notch1* in MDSC from TB mice was even higher than in IMC from control mice (Fig. 2B and C). Similar results were obtained in experiments *in vitro* where bone marrow HPCs were cultured in the presence of TCM. Significant reduction in the expression of *hes1* was observed, whereas no differences were seen in the expression of *notch1* and *notch2* (Fig. 2D). Thus, these data indicated that decrease in Notch signaling was not the result of downregulation of the receptors, their cleavage and nuclear translocation, or the amount of CSL.

We next addressed whether downregulation of Notch ligands could contribute to a reduced Notch signaling in HPCs. Dramatic downregulation of all studied Notch ligands (Jag1, Jag2, Dll1, 3, and 4) was found in bone marrow from CT26 TB mice as compared with naïve tumor-free mice (Fig. 2E).

We hypothesized that if decreased expression of Notch ligands was responsible for downregulation of signaling, then Notch signaling and dendritic cell differentiation should be restored by incubating cells with immobilized ligand. To test this hypothesis, HPCs were cultured overnight with Dll1 immobilized on plastic. In the absence of TCM, Dll1 caused 6-fold increase in *hes1* expression. However, this upregulation was completely abrogated in the presence of TCM (Fig. 2F). Similar results were obtained in CSL luciferase reporter assay (Fig. 2G). Thus, Notch ligand could not restore the blockade of the Notch signaling caused by TCM, which indicated that this block was downstream of the receptor.

We next tested the effect of activation of Notch signaling on dendritic cell differentiation. HPCs were cultured for 6 days with GM-CSF on immobilized Dll1 in the presence of TCM. In the absence of TCM, Dll1 promoted dendritic cell differentiation. HPC were cultured for 6 days with GM-CSF on immobilized Dll1 in the presence of TCM. In the absence of TCM, Dll1 caused 6-fold increase in *hes1* expression. However, this upregulation was completely abrogated in the presence of TCM (Fig. 2F). Similar results were obtained in CSL luciferase reporter assay (Fig. 2G). Thus, Notch ligand could not restore the blockade of the Notch signaling caused by TCM, which indicated that this block was downstream of the receptor.
hallmark of dendritic cell activity. TCM dramatically reduced allogeneic MLR in the cells generated from HPCs and abrogated stimulatory effect of Dll1 (Fig. 3B). These data indicated that the Notch ligand Dll1 was not able to rescue inhibited dendritic cell differentiation and MDSC expansion caused by TCM.

To bypass receptor–ligand interaction, we induced Notch signaling by overexpressing ICN1 using a retroviral construct containing ICN1 and GFP. The GFP served to track cells with ICN1 expression. In the absence of TCM, expression of ICN1 significantly increased the proportion of dendritic cells (Fig. 3C). However, the overexpression of ICN1 was not able to overcome the defect in dendritic cell differentiation or accumulation of IMC caused by TCM (Fig. 3C).

We also tested possible effect of ICN1 overexpression on HPC differentiation in vivo. Lin−c−kit+ myeloid progenitor cells were sorted from bone marrow of naïve CD45.2+ mice, infected with retrovirus expressing ICN1, and then injected intravenously into lethally irradiated naïve or EL4 TB CD45.1 congenic mice (Fig. 3D). Two weeks after the transfer, the donor cells (CD45.2+) transplanted with ICN1 (GFP+) cells were evaluated in spleens of recipient mice. We observed that HPC transfected with control virus and transferred to TB mice produced significantly smaller proportion of dendritic cells but higher proportion of MDSC than HPC transferred to control mice (Fig. 3D and E). Expression of ICN1 in HPC transferred to naïve recipients resulted in upregulation of dendritic cells and macrophages' differentiation. However, in TB mice no...
improvement in dendritic cell differentiation was seen and changes in the proportion of MDSC were not statistically significant (Fig. 3E). Thus, activation of Notch signaling either by triggering the receptors or by overexpressing ICN1 did not overcome the defect in dendritic cell differentiation observed in TB mice.

Disruption of interaction between CSL and Notch in HPC and myeloid cells in cancer

Formation of Notch/CSL complex is necessary for the activation of the transcription of target genes. To assess physical interaction between Notch and CSL, HPCs were transduced with a retroviral ICN1-myc construct. Myc-specific antibody was used to pull-down ICN1 and membranes were probed with anti-CSL antibody. In HPC, cultured in control medium, the association between ICN and CSL was readily detectable. In contrast, in HPC, cultured in the presence of TCM, it was substantially reduced (Fig. 4A). Culture of HPC with TCM resulted in an increase in serine phosphorylation of ICN1 (Fig. 4A), whereas no tyrosine phosphorylation was detected (data not shown).

Analysis of the structure of Notch suggested a number of serine residues in RAM domain, phosphorylation of which could affect binding of ICN1 with CSL. For instance, phosphorylation of serine 1901 and threonine 1898 were implicated in decreased formation of a Notch–Maml1–CSL ternary complex on DNA (33). To clarify the possible role of the specific serine residues in ICN/CSL interaction, we made ICN1 several constructs with mutations in serine residues in RAM domain of ICN1. Mutations in S1779 and S1856 were not sufficient to abolish interaction between ICN1 and CSL (Fig. 4B). However, after mutations in S1901 and T1898, ICN1 construct lost binding to CSL in MDSC (Fig. 4C) and was associated with substantially reduced level of serine phosphorylation in the presence of TCM (Fig. 4C). These data suggested that serine phosphorylation of ICN1 in cancer may block its binding to CSL and thus prevents the transcription of target genes.
CK2 regulated Notch activity in myeloid cells in cancer

What could induce Notch phosphorylation in myeloid cells in cancer? Serine/threonine CK2 previously was implicated in regulation of Notch activity under physiological conditions (33). We evaluated the presence of CK2 protein in Gr-1\(^+\)CD11b\(^+\) myeloid cells and found that the amount of catalytic \(\alpha\) domain of CK2 protein was similar between control and TB mice (Fig. 4D). However, when kinase activity of CK2 was measured, it was significantly higher in HPC (Fig. 4E) or MDSC (Fig. 4F) than in cells from control mice. Gr-1\(^+\)CD11b\(^+\) myeloid cells generated from HPC in the presence of TCM had higher CK2 activity than Gr-1\(^+\)CD11b\(^+\) cells generated in the control medium (Fig. 4G). In humans, we observed similarly that CD14\(^+\)/CD11b\(^+\)/CD15\(^+\) MDSC isolated from blood of renal cell carcinoma patients and healthy donors (n = 3). In all experiments, statistically significant difference from control: *P < 0.05; **P < 0.01.

These results suggest that upregulation of CK2 activity may play a role in regulation of Notch activity in cancer. To test this possibility directly, 293T cells were transfected with the plasmid encoding catalytic \(\alpha\) subunit of CK2 gene (cnk2a1; Fig. 5A). Cotransfection of CK2 plasmid with ICN1-myc plasmid caused phosphorylation of ICN1 and inhibited interaction of ICN1 with CSL (Fig. 5B). Csnk2a1 expression vector was cloned to a retroviral construct expressing GFP. Enriched bone marrow HPC were infected with control and CK2 retroviruses and cultured for 5 days with GM-CSF. Overexpression of CK2 in HPC reduced dendritic cell differentiation by half, whereas the proportion of Gr-1\(^+\)CD11b\(^+\) cells increased more than 2-fold (Fig. 5C). Thus, upregulation of CK2 in HPC blocked Notch signaling, inhibited dendritic cell differentiation, and caused accumulation of IMC.

Next, we tested the possibility that downregulation of CK2 might improve Notch signaling in myeloid cells from TB mice.
MDSCs were isolated from EL4 TB mice, transfected with either control or CK2α siRNA, and cultured for 24 hours in either complete medium or with TCM. Two different sets of siRNA, targeting different parts of the sequence were used (Fig. 5D). We observed that MDSC transfected with control siRNA cultured with TCM had significantly ($P < 0.01$) lower hes1 expression than cells cultured in complete medium. The treatment with the CK2 siRNA did not affect hes1 expression in cells cultured in complete medium but substantially reduced the effect of TCM on hes1 expression (Fig. 5E). Thus, these data indicated that CK2 negatively regulated Notch activity in myeloid cells in cancer.

**Inhibition of CK2 improves Notch signaling and differentiation of myeloid cells in cancer**

We asked whether pharmacological inhibition of CK2 may increase Notch signaling in myeloid cells and consequently restore their differentiation in cancer. We used the selective CK2 inhibitor, tetramodocinnamic acid $\alpha$-44kDa (TBCA; ref. 34). Treatment with TBCA did not affect CK2 activity in myeloid cells cultured without TCM, but at concentrations 1.2 to 2.5 $\mu$mol/L it abrogated increased activity of CK2 in MDSC (Fig. 6A). At those concentrations, no effect on cell viability was seen (data not shown). Inhibition of CK2 abrogated serine phosphorylation of ICN caused by TCM and restored interaction between ICN and CSL (Fig. 6B).

To test the effect of CK2 inhibitor on dendritic cell differentiation, TBCA was added to the culture of HPC with TCM. Addition of TBCA to the cultures abolished negative effect of TCM on dendritic cell differentiation (Fig. 6C). TCM caused expansion of PMN-MDSC from HPC, which was not corrected by Dll1 (Fig. 6D). However, TBCA in combination with Dll1 substantially reduced the effect of TCM on PMN-MDSC expansion (Fig. 6D).

We tested the possible effect of *in vivo* treatment with the CK2 inhibitor on 2 experimental models: CT26 and EG-7 (EL-4 tumor cells expressing chicken ovalbumin). *In vitro* testing in MTT assay revealed lack of TBCA toxicity in both cell lines at concentration as high as 10 $\mu$mol/L (data not shown). First, we tested mice with established, large CT-26 tumors (>1 cm in diameter) with short (6 days) treatment protocol. Mice were treated with intraperitoneal (i.p.) injections of TBCA and cells were evaluated 2 days after the finish of the treatment. One week of TBCA treatment did not significantly affect the size of established large tumors (Fig. 7A). Mice did not display any gross signs of toxicity (changes in body weight, posture, or behavior). TBCA caused significant decrease in CK2 activity in myeloid cells, both in bone marrow and spleens (Fig. 7B). This was associated with significant increase in the expression of...
hes1 in these cells (Fig. 7C). Treatment of mice with TBCA resulted in significant increase in the proportion and absolute number of dendritic cells in spleens (Fig. 7D and E) or LN (Fig. 7D and F). Splenocytes from TBCA-treated mice demonstrated substantially higher stimulatory activity in allogeneic MLR, reflecting the presence of higher proportion of dendritic cells (Fig. 7G). Thus, inhibition of CK2 activity resulted in improved Notch signaling and dendritic cell differentiation in TB mice. To assess whether these changes in myeloid cells can result in antitumor effect, we used immunogenic EG-7 tumor and longer treatment. Mice with palpable tumors were treated for 2 weeks with TBCA. No signs of toxicity were evident. TBCA caused significant decrease in the tumor growth ($P = 0.01$; Fig. 7H).

Discussion

In this study, we observed dramatic reduction of Notch signaling in HPC and myeloid cells from TB mice and patients with cancer as compared with their control counterparts. Because PMN-MDSC decreased expression of Notch ligands in TB hosts was previously described (35), this could explain the observed defect in Notch signaling. We have confirmed substantial downregulation of all Notch ligands in bone marrow of TB mice. However, to our surprise, this decrease was not responsible for the downregulation of Notch signaling. Neither Dll1, a potent activator of Notch signaling, nor overexpression of ICN1 were able to restore Notch signaling or myeloid cell differentiation in HPC isolated from TB mice or cultured in the presence of tumor-derived factors. This observation, together with the fact that the amount of cleaved ICN1 translocated to the nuclei was not changed, indicated that the defect in Notch signaling in cancer was downstream of the receptor. Formation of ternary complex is required for activation of canonical Notch signaling. Although this complex includes several different components, the central element of that complex is the interaction between ICN and CSL. We found that this physical interaction between ICN1 and CSL was disrupted in myeloid cells from TB mice. This disruption was associated with serine phosphorylation of ICN1. Consistent with recent observation made under physiological conditions...
(33), mutations in S1901 and T1898 completely abrogated physical interaction between ICN1 and CSL in MDSC. Taken together, these data suggested that inhibition of Notch signaling in HPC and myeloid cells in cancer could be the result of increased serine phosphorylation of RAM domain of Notch and disruption of formation of ternary complex. Our data implicated CK2 as the kinase possibly responsible for this phenomenon.

Serine/threonine kinase CK2 is ubiquitously expressed in a variety of cell types and tissues, and is considered to be constitutively active. CK2 is involved in every stage of cell cycle, by phosphorylating proteins required for G0–G1, G1–S, and G2–M transitions. CK2 may act as a general regulator of all cellular transcription and apoptosis (36). The function of CK2 in normal hematopoiesis is largely unknown. However, there are some indications that CK2 may play an important role in this process. For instance, it has been shown that CK2 activate Wnt and hedgehog signaling pathways (37, 38). However, CK2 negatively regulate PTEN activity (39) and activate Akt (40). In addition, CK2 stimulates activity of several transcription factors involved in hematopoiesis: c-Myb (41), PU.1 (42), and Ets-family transcription factors Sp1 and Sp3 (43). Although CK2 is constitutively active, its overexpression was documented in the number of solid and hematologic malignancies (44, 45). Our data indicate that although the amount of this enzyme was not changed in myeloid cells from TB mice, its activity was substantially higher than in the corresponding control leukocytes. Our experiments demonstrated CK2 upregulation was caused by tumor-derived factors, although the nature of these factors needs to be elucidated. Overexpression of catalytic domain of CK2 was sufficient to disrupt interaction between Notch and CSL and, most importantly, to block dendritic cell differentiation, which mimics the conditions observed in TB hosts. Downregulation of CK2 in MDSC improved Notch signaling. These data support the role of CK2 in negative regulation of Notch signaling and myeloid cell differentiation.

Figure 7. Effect of CK2 inhibition on dendritic cell differentiation in vivo. CT26 TB mice were treated with TBCA [1.7 mg in 200 μL DMSO/water (1:4), i.p. daily] or vehicle alone (Con) for 6 days. Cells were collected on day 7. Each experiment includes four mice. A, tumor size in treated mice; B, CK2 activity of MDSC isolated from bone marrow and spleens; C, expression of hes1 mRNA in the same cells; D, proportion of myeloid cells in spleens and lymph nodes. E and F, absolute number of cells in spleens (E) and lymph nodes (F). G, allogeneic MLR of splenocytes from treated mice. T cells from C57BL/6 mice were used as responder cells. In all experiments, ⁎, P < 0.05 from control. H, EG-7 tumors were established subcutaneously by injecting 0.5 × 10⁶ cells. TBCA treatment started on day 7 after tumor inoculation and was continued for 14 days. Tumor size was measured. Each group included 3 mice.
in cancer. From this perspective, pharmacologic inhibition of CK2 may have value in an immunotherapeutic anticancer approach.

Our initial data supported this possibility. We used selective CK2 inhibitor TBCA. It was described to inhibit CK2 at 200 nM values of 0.11 μM/L, without having any comparable effect on a panel of 28 protein kinases [34]. In our experiments, TBCA had little effect of CK2 activity in control myeloid cells but at concentration 0.6 μM/L, TBCA significantly attenuated the increased activity in myeloid cells from TB mice. Similarly, TBCA did not have effect on Notch signaling in control myeloid cells, but restored inhibited Notch signaling in the cells from TB hosts. These results may suggest that TBCA could target only elevated levels of CK2 activity.

We observed interesting dichotomy in changes in Notch signaling between PMN-MDSC and M-MDSC. Notch signaling was substantially reduced in PMN-MDSC as compared with M-MDSC during incubation with TCM. These results are consistent with our observations made in the total population of Gr-1
d cells, but restored inhibited Notch signaling in the cells from TB hosts. These results may suggest that TBCA could target only elevated levels of CK2 activity.

Experiments in vivo demonstrated that CK2 inhibitor significantly increased differentiation of dendritic cells and inhibited MDSC expansion in TB mice without displaying signs of toxicity. Thus, this study is a first report describing the mechanism that negatively regulates Notch signaling in myeloid cells in cancer and functional consequences of that down-regulation. We implicated upregulation of CK2 in this process. In the future, a more detailed analysis of toxicity and the effect of the CK2 inhibitor on other immune cells will be necessary to establish its potential therapeutic utility. However, our findings here suggest that this approach can be of interest to improve regulation of myeloid cell function in cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: P. Cheng, V. Kumar, D. Gabrilovich
Development of methodology: P. Cheng, V. Kumar, H. Liu, D. Gabrilovich
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Cheng, V. Kumar, H. Liu, J.-I. Youn, M. Fishman
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P. Cheng, V. Kumar, H. Liu, S. Sherman, D. Gabrilovich
Writing, review, and/or revision of the manuscript: P. Cheng, H. Liu, J.-I. Youn, M. Fishman, D. Gabrilovich
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Sherman
Study supervision: D. Gabrilovich

Acknowledgments
The authors thank A. Lawrence and chemistry core of H. Lee Moffitt Cancer Center for synthesis of TBCA. The authors thank Dr. B. Osborne (University of Massachusetts) for providing us with ICN1-Myc construct.

Grant Support
This study was supported by NIH grant R01CA141438 to D. Gabrilovich. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 14, 2013; revised October 17, 2013; accepted October 23, 2013; published OnlineFirst November 12, 2013.

References


Effects of Notch Signaling on Regulation of Myeloid Cell Differentiation in Cancer

Pingyan Cheng, Vinit Kumar, Hao Liu, et al.

*Cancer Res* 2014;74:141-152. Published OnlineFirst November 12, 2013.

**Updated version**
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-1686

**Supplementary Material**
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/11/12/0008-5472.CAN-13-1686.DC1

**Cited articles**
This article cites 46 articles, 21 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/1/141.full.html#ref-list-1

**Citing articles**
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
/content/74/1/141.full.html#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.